Literature DB >> 16505094

Protein tyrosine phosphatase PRL-3 in malignant cells and endothelial cells: expression and function.

Cecile Rouleau1, Andre Roy, Thia St Martin, Michael R Dufault, Paula Boutin, Dapei Liu, Mindy Zhang, Kristin Puorro-Radzwill, Lori Rulli, Dave Reczek, Rebecca Bagley, Ann Byrne, William Weber, Bruce Roberts, Katherine Klinger, William Brondyk, Mariana Nacht, Steve Madden, Robert Burrier, Srinivas Shankara, Beverly A Teicher.   

Abstract

Protein tyrosine phosphatase PRL-3 mRNA was found highly expressed in colon cancer endothelium and metastases. We sought to associate a function with PRL-3 expression in both endothelial cells and malignant cells using in vitro models. PRL-3 mRNA levels were determined in several normal human endothelial cells exposed or unexposed to the phorbol ester phorbol 12-myristate 13-acetate (PMA) and in 27 human tumor cell lines. In endothelial cells, PRL-3 mRNA expression was increased in human umbilical vascular endothelial cells and human microvascular endothelial cells (HMVEC) exposed to PMA. An oligonucleotide microarray analysis revealed that PRL-3 was among the 10 genes with the largest increase in expression on PMA stimulation. Phenotypically, PMA-treated HMVEC showed increased invasion, tube formation, and growth factor-stimulated proliferation. A flow cytometric analysis of cell surface markers showed that PMA-treated HMVEC retained endothelial characteristics. Infection of HMVEC with an adenovirus expressing PRL-3 resulted in increased tube formation. In tumor cells, PRL-3 mRNA levels varied markedly with high expression in SKNAS neuroblastoma, MCF-7 and BT474 breast carcinoma, Hep3B hepatocellular carcinoma, and HCT116 colon carcinoma. Western blotting analysis of a subset of cell line lysates showed a positive correlation between PRL-3 mRNA and protein levels. PRL-3 was stably transfected into DLD-1 colon cancer cells. PRL-3-overexpressing DLD-1 subclones were assessed for doubling time and invasion. Although doubling time was similar among parental, empty vector, and PRL-3 subclones, invasion was increased in PRL-3-expressing subclones. In models of endogenous expression, we observed that the MCF-7 cell line, which expresses high levels of PRL-3, was more invasive than the SKBR3 cell line, which expresses low levels of PRL-3. However, the MDA-MB-231 cell line was highly invasive with low levels of PRL-3, suggesting that in some models invasion is PRL-3 independent. Transfection of a PRL-3 small interfering RNA into MCF-7 cells inhibited PRL-3 expression and cell invasion. These results indicate that PRL-3 is functional in both endothelial cells and malignant cells and further validate PRL-3 as a potentially important molecular target for anticancer therapy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16505094     DOI: 10.1158/1535-7163.MCT-05-0289

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  26 in total

Review 1.  Targeting protein tyrosine phosphatases for anticancer drug discovery.

Authors:  Latanya M Scott; Harshani R Lawrence; Saïd M Sebti; Nicholas J Lawrence; Jie Wu
Journal:  Curr Pharm Des       Date:  2010-06       Impact factor: 3.116

2.  Protein expression following gamma-irradiation relevant to growth arrest and apoptosis in colon cancer cells.

Authors:  Daniella Pfeifer; Asa Wallin; Birgitta Holmlund; Xiao-Feng Sun
Journal:  J Cancer Res Clin Oncol       Date:  2009-06-06       Impact factor: 4.553

3.  Protein-tyrosine phosphatase 4A3 (PTP4A3) promotes vascular endothelial growth factor signaling and enables endothelial cell motility.

Authors:  Mark W Zimmerman; Kelley E McQueeney; Jeffrey S Isenberg; Bruce R Pitt; Karla A Wasserloos; Gregg E Homanics; John S Lazo
Journal:  J Biol Chem       Date:  2014-01-08       Impact factor: 5.157

Review 4.  Modulation of VEGF receptor 2 signaling by protein phosphatases.

Authors:  Federico Corti; Michael Simons
Journal:  Pharmacol Res       Date:  2016-11-23       Impact factor: 7.658

5.  Prognostic and metastatic value of phosphatase of regenerating liver-3 in invasive breast cancer.

Authors:  Ru-Tian Hao; Xiao-Hua Zhang; Yi-Fei Pan; Hai-Guang Liu; You-Qun Xiang; Li Wan; Xiu-Ling Wu
Journal:  J Cancer Res Clin Oncol       Date:  2010-02-06       Impact factor: 4.553

6.  Augmented expression of urokinase plasminogen activator and extracellular matrix proteins associates with multiple myeloma progression.

Authors:  Rehan Khan; Nidhi Gupta; Raman Kumar; Manoj Sharma; Lalit Kumar; Alpana Sharma
Journal:  Clin Exp Metastasis       Date:  2014-05-08       Impact factor: 5.150

7.  Using LongSAGE to Detect Biomarkers of Cervical Cancer Potentially Amenable to Optical Contrast Agent Labelling.

Authors:  Julie M Kneller; Thomas Ehlen; Jasenka P Matisic; Dianne Miller; Dirk Van Niekerk; Wan L Lam; Marco Marra; Rebecca Richards-Kortum; Michelle Follen; Calum Macaulay; Steven J M Jones
Journal:  Biomark Insights       Date:  2007-12-11

Review 8.  Phosphatase of regenerating liver: a novel target for cancer therapy.

Authors:  Amanda M Campbell; Zhong-Yin Zhang
Journal:  Expert Opin Ther Targets       Date:  2014-03-01       Impact factor: 6.902

9.  PRL-3 siRNA inhibits the metastasis of B16-BL6 mouse melanoma cells in vitro and in vivo.

Authors:  Feng Qian; Yu-Pei Li; Xia Sheng; Zi-Chao Zhang; Ran Song; Wei Dong; Shao-Xian Cao; Zi-Chun Hua; Qiang Xu
Journal:  Mol Med       Date:  2007 Mar-Apr       Impact factor: 6.354

10.  PRL-3 promotes the motility, invasion, and metastasis of LoVo colon cancer cells through PRL-3-integrin beta1-ERK1/2 and-MMP2 signaling.

Authors:  Lirong Peng; Xiaofang Xing; Weijun Li; Like Qu; Lin Meng; Shenyi Lian; Beihai Jiang; Jian Wu; Chengchao Shou
Journal:  Mol Cancer       Date:  2009-11-24       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.